Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890

July 29, 2020 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890

PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Amgen pays Arrowhead $20 million milestone for start of Phase 2 study of AMG 890 formerly ARO-LPA